Compare Johnson & Johnson (JNJ) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs VNET Group Inc — how do they compare? Johnson & Johnson trades at $249.36 (market cap $598.96B), while VNET Group Inc trades at $7.77 (market cap $2.19B). The key difference: Johnson & Johnson is far larger — about 273.5× VNET Group Inc's market cap, and Johnson & Johnson pays a 2.15% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| JNJ | VNET | |
|---|---|---|
Market Cap | $598.96B | $2.19B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $14.03 |
52-Week Low | $164.36 | $7.34 |
Enterprise Value | $631.90B | $5.32B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VNET Group trades at $7.675, up 3.86% today, but technical indicators signal a bearish trend with moving averages unanimously negative. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investments in AI and data center capacity, alongside a class action settlement announcement.
The outlook is mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and bearish technicals pose risks. Investment opportunity hinges on execution of growth initiatives in AI-driven demand, while key risks include profitability challenges and competitive pressures in the data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
